Pronova BioPharma ASA

Pronova BioPharma ASA (OSL:PRON) 9 January, 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL). Presentation material in connection with CEO Per-Oluf Olsen's presentation at SEB Enskilda Nordic Seminar in Copenhagen, 8 January 2009, is attached.

Pronova BioPharma ASA (OSL:PRON) Issuers of listed transferable securities are required to provide Oslo Stock Exchange with an annual summary of information made available to the public, cf the Stock Exchange Regulations, section 5-2, §5.

Pronova BioPharma ASA (OSL:PRON) 9 January 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces changes in the group's management team structure in order to create a stronger focus on group management, simplify the reporting structure, and to ensure better alignment of staff functions, line management and cross-functional/cross-border issues.

Pronova BioPharma ASA (OSL:PRON) 6 January 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "Company") today announces that it has filed a Terminal Disclaimer in US patent No. 5,656,667 ('667 Patent) with the U.S. Patent & Trademark Office. The '667 Patent is listed in the FDA's Orange Book with respect to Lovaza(TM). A Terminal Disclaimer was filed by Pronova BioPharma to disclaim the terminal part of the statutory term under 35 U.S.C. § 154 of the '667 patent which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 5,502,077 ('077 Patent), also listed in the Orange Book with respect to Lovaza(TM). With patent term extension under 35 U.S.C. § 156, the '677 patent will now expire on April 10, 2017.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 17 November 2008 purchased 37 000 of its own shares in the market at a price of NOK 23,10. After this transaction, the company holds 200 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares. Today's transaction ends the company's share buy back.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 14 November 2008 purchased 54 000 of its own shares in the market at a price of NOK 23,00 per share and intends to purchase an additional 37 000 shares in the market. After this transaction, the company holds 163 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 12 November 2008 purchased 50 000 of its own shares in the market at a price of NOK 20,92 per share and intends to purchase an additional 91 000 shares in the market. After this transaction, the company holds 109 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 11 November 2008 purchased 37 000 of its own shares in the market at a price of NOK 19,95 per share and intends to purchase an additional 141 000 shares in the market. After this transaction, the company holds 59 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) 11 November, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that a study to be presented at the American Heart Association Scientific Sessions in New Orleans, USA, shows that Lovaza/Omacor co-administered with atorvastatin significantly improves non-HDL cholesterol and triglycerides compared with atorvastatin alone. An abstract of the study was published on the AHA's conference website http://www.abstractsonline.com/plan/start.aspx?mkey=%7BD78A4520%2D4797%2D409B%2DBF84%2D2F89D1773D57%7D .

Pronova BioPharma ASA (OSL:PRON) 10 November, 2008, Lysaker, Norway: Primary insider, vice president legal affairs, Cecilia Orheim, has today bought 38 400 shares in the company.The shares were bought at an average share price of NOK 19.47. Ms Orheim's total number of shares held after todays purchase is 74 400.